RAPAPRO TABLETS

Product Description

RapaPro (Rapamycin Tablets 1 mg) contains Sirolimus, an immunosuppressive agent formulated using advanced nanoparticle technology to enhance solubility and improve oral bioavailability. Each film-coated tablet provides 1 mg of Sirolimus and is intended for oral administration.

Sirolimus works by inhibiting the mammalian target of rapamycin (mTOR) pathway, thereby suppressing T-lymphocyte activation and proliferation. This action helps prevent organ transplant rejection and regulates immune responses. The nanoparticle formulation ensures consistent drug absorption and reliable therapeutic performance.

RapaPro is primarily indicated for the prophylaxis of organ rejection in renal (kidney) transplant recipients, generally in combination with other immunosuppressive agents such as corticosteroids and calcineurin inhibitors, as directed by the treating physician. It may also be prescribed for other approved indications based on clinical judgment and local treatment guidelines.

Manufactured under stringent quality standards, RapaPro film-coated tablets are designed to provide consistent potency, stability, and efficacy. Treatment with Sirolimus requires regular monitoring of blood drug concentrations, renal function, liver function, lipid profile, and complete blood counts to ensure optimal therapeutic outcomes and minimize adverse effects.